Talk:Oseltamivir total synthesis
![]() | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
Wiki Education Foundation-supported course assignment
[edit] This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Mlasky8. Peer reviewers: Mdbreshears.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 05:52, 17 January 2022 (UTC)
Great start, one request
[edit]This article is generally nicely done. It would help if each example of the total synthesis (a) was in the same style vis-a-vis image (ChemDraw conventions, use of colour, presentation and abbreviation of reagents, etc.) , and (b) was explained in a parallel style, leading to the level of detail being comparable in each synthesis. Cheers, Le Prof — Preceding unsigned comment added by Leprof 7272 (talk • contribs) 12:40, 15 May 2014 (UTC)
And, one further
[edit]To move the article closer to being appreciated by a more general audience, I would suggest that we move from jargon specific to our field (e.g., "KHMDS") to a bit more elaborated text (e.g., "the non-nucleophilic strong base potassium bis(trimethylsilyl)amide"), so that the reader does not have to link out repeatedly to begin to understand what is going on in each synthesis. As well, there is a little too much focus in the description on the tactics, and not enough of the strategy of the preparations (for each, and overall). Cheers. Le Prof Leprof 7272 (talk) 12:55, 15 May 2014 (UTC)
New Ideas:
[edit]My plan:
My plan is going to be to highlight the total synthesis done by the Hayashi group in 2009[1]. I intended to discuss the synthetic strategies used in each of the three one-pot operations, as well as, highlight how the procedure is suitable for large-scale production. I will also display the overall scheme for the total synthesis. I will also add more information to the introduction of Oseltamivir total synthesis to make the page more relevant because right now it does not work well.
Mlasky8 (talk) 17:03, 21 November 2017 (UTC)
- By all means go ahead, if you are going to expand the article try to include all efforts not that of just the Hayashi group , the list is not complete. Ignore the "notability" tag: the editors did not use primary literature (they do not have access or read the lab notes of the scientists involved, would be a bit strange) but relied solely on peer-reviewed articles (secondary literature) from respectable journals. Since the creation of the article in 2007, a Chemical Reviews article has appeared on the topic in 2009, the editor who put up the tag in 2017 could have included the cite but did not for some reason. V8rik (talk) 18:21, 21 November 2017 (UTC)
- Thanks for the good work, I have added another cite, the editor I have mentioned above did not bother to respond V8rik (talk) 18:04, 19 December 2017 (UTC)
References
- ^ Ishikawa, Hayato; Suzuki, Takaki; Hayashi, Yujiro (2009). "High-yielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations". Angewandte Chemie (International Ed. in English). 48 (7): 1304–1307. doi:10.1002/anie.200804883. ISSN 1521-3773. PMID 19123206.
- ^ Yarnell, Amanda. "Complexity Of Tamiflu Manufacturing May Hamper On Demand Production". http://pubs.acs.org/cen/news/83/i35/8335tamiflu1.html. 83: 22.
{{cite journal}}
: External link in
(help)|journal=
- ^ MCCOY, MICHAEL (2006-03-20). "Roche Unveils Tamiflu Production Network". Chemical & Engineering News Archive. 84 (12): 10. doi:10.1021/cen-v084n012.p010a. ISSN 0009-2347.
- ^ Seijo, Bibiana Campos (2016-07-18). "Juno, Tamiflu, and Theranos". C&EN Global Enterprise. 94 (29): 3–3. doi:10.1021/cen-09429-editorial.
- ^ Magano, Javier (2009-09-09). "Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza". Chemical Reviews. 109 (9): 4398–4438. doi:10.1021/cr800449m. ISSN 0009-2665.